AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP)
Description: Abiraterone acetate plus prednisone (AAP) will be administered orally.
Study NCT04972721 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
Study NCT04713267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ISABel Bed 1
Description: During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
Study NCT05787808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calsium, Vitamin D, Jarlsberg cheese
Description: Oral
Study NCT05620732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin18.2 CAR-T cells
Description: patients treated with Claudin18.2 CAR-T cells
Study NCT05522205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulated cannabis access in pharmacies
Description: The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
Study NCT05911048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
Description: boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
Study NCT05911048 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
Description: boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT with donor peripheral blood stem cells
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT with donor peripheral blood stem cells
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Undergo stem cell mobilization with G-CSF
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor
Description: Undergo stem cell mobilization with G-CSF
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation Conditioning Regimen
Description: Receive pre transplant conditioning
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hematopoietic Cell Transplantation Conditioning Regimen
Description: Receive pre transplant conditioning
Study NCT06059391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study NCT06059391 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pheresis
Description: Undergo apheresis
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IM
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell Mobilization Therapy
Description: Undergo stem cell mobilization with G-CSF
Study NCT06059391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stem Cell Mobilization Therapy
Description: Undergo stem cell mobilization with G-CSF
Study NCT04833270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM non-pharmacological treatment group
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
Study NCT04833270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment group
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
Study NCT04880798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 124I PET/CT
Description: The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin >100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
Study NCT05780814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Description: The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
Study NCT05780814 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Control (EDU)
Description: Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
Study NCT04591990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of AVP
Description: Administration of AVP
Study NCT04591990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo AVP
Description: Administration of placebo AVP
Study NCT04591990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo hydrocortisone
Description: Administration of placebo hydrocortisone
Study NCT04591990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of hydrocortisone
Description: Administration of hydrocortisone
Study NCT06149364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISKE
Description: The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken.
Study NCT06482788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab (anti-PD-L1) + XELOX
Description: Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks).
Study NCT06183827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency Medical Service intervention
Description: Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control.
Study NCT06183827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Medical Service intervention
Description: Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control.
Study NCT06546956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Breathwork Intervention
Description: GRMT has three core components: respiratory regulation (i.e., sustained conscious connected breathing pattern into the upper chest where there is no pause between inhale and exhale), mindfulness of somatic sensations while breathing (i.e., interoceptive awareness with acceptance), and relaxation of physical tension. These components are the primary focus in every breathwork session. The intervention is delivered 1-on-1 in-person with a trained facilitator. Participants lay supine throughout the 60 minute session. The facilitator observes the participant's breathing pattern and guides the participant to apply the three core components. Each session ends with spontaneous, relaxed breathing and an opportunity to briefly share what happened during the session.
Study NCT04491084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT3 Ligand (CDX-301)
Description: Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.
Study NCT04491084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody (CDX-1140)
Description: CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
Study NCT01491139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Given twice daily. Exposure will escalate by daily dose and duration.
Study NCT01491139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Dose will be 35mg/m2 i.v. once weekly.
Study NCT01491139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Total dose will be 70Gy in 35 fractions over 7 weeks.
Study NCT04498325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Supplied by study
Study NCT05797935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
Study NCT06051838 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: if the patients is TD positive, we recommond careful surgery and pathological examination.
Study NCT04498325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied by study
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for research purposes
Description: Prior to injection (Day 0), Day 7, and Day 14
Study NCT05108350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
Study NCT05108350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
Study NCT05108350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
Study NCT05108350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood for research purposes
Description: Prior to injection (Day 0), Day 7, and Day 14
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for pharmacokinetic samples
Description: -Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal, oropharyngeal, or saliva swab
Description: -Prior to study treatment, Day 4(optional), Day 7, and Day 14
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasopharyngeal, oropharyngeal, or saliva swab
Description: -Prior to study treatment, Day 4(optional), Day 7, and Day 14
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for anti-drug antibody (ADA)
Description: Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
Study NCT04498325 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood for anti-drug antibody (ADA)
Description: Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
Study NCT04807205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Non-Invasive Treatment
Description: Self-controlled single-arm group using the Elite IQ device
Study NCT06350435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFO) with metatarsal pads
Description: A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath
Study NCT06350435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prefabricated foot orthoses (PFO) without metatarsal pads
Description: A pair of prefabricated foot orthoses only
Study NCT05590416 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
Study NCT04484142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1062a
Description: DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
Study NCT06306404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens and Progestogens
Description: Menopausal Hormone Therapy, formerly known as Hormone Replacement Therapy (HRT), is a medical treatment that involves the use of hormones to relieve the symptoms of menopause and to reduce the risk of certain long-term health conditions associated with menopause. Menopause is a natural biological process that occurs when a women's ovaries stop producing effects, and her estrogen and progesteron hormone levels subsequently decrease. MHT typically involves administration of a combination of sec steroids.~In this study MHT consists of estradiol transdermal patches (50 mcg (Systen), which provide a stable release of estradiol and lead to more stable blood levels. This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT guidelines.
Study NCT06306404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy
Description: CBTi is a guided, internet-based cognitive behavioral therapy program for insomnia, containing information and exercises on sleep. It consists of five online sessions:~1. Psycho-education on sleep, disordered sleep and sleep hygiene (i.e. general guidelines about health and environmental factors influencing sleep),~2. Sleep restriction (i.e. restrict time in bed to the average sleep time) and stimulus control training (i.e. reinforce association of bed with sleeping),~3. Rumination and relaxation techniques,~4. Cognitive restructuring (i.e. changing misconceptions about sleep),~5. Relapse prevention.
Study NCT04491084 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
Study NCT05113771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liafensine
Description: Liafensine
Study NCT04491084 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
Study NCT03113084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin UQ subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study NCT03113084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin FK subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study NCT05122078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI
Description: Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
Study NCT05113771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05339711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Pet Therapy/Robot Cat Group
Description: İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher.
Study NCT05339711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet Therapy/Betta Fish Group
Description: İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
Study NCT05326347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
Study NCT05491200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel based short DAPT
Description: Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
Study NCT05491200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel based standard DAPT
Description: Prasugrel based DAPT for 1 year
Study NCT05491200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT guided revascularization
Description: OCT guided revascularization of the non-culprit lesions
Study NCT05491200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided revascularization
Description: Angio guided revascularization of the non-culprit lesions
Study NCT04835714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963